

09-08-04.

01P		ype a plus sign (+) inside this box →  der the Paperwork Reduction Act of 1995, no	persons are required	to respond to a collection of inf	PTO/SB/21 (05-03) Approved for use through 04/30/2003. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE formation unless it displays a valid OMB control number.
				Application Number	10/661,105
PADEMA		TRANSMITTAL		Filing Date	September 12, 2003
		FORM	_	First Named Inventor	KEIRSTEAD, HANS S.
		1 Ortin		Group Art Unit	1651
		(to be used for all correspondence after init	tial filing)	Examiner Name	
		Total Number of Pages in This Submissi	on 3	Attorney Docket Number	IRVN-009CON
			ENCLOSUR	ES (check all that apply)	
		Fee Transmittal Form  Fee Attached  Amendment / Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement SB08A (1pg.)  Certified Copy of Priority Documents  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Control   Cont	ing-related Papers  n to Convert to a onal Application of Attorney, Revocation e of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information  Status Letter  Other Enclosure(s) Copy of Search Report 6 Cited References Postcard
			<del></del>	ICANT, ATTORNEY, OF	KAGENI
	Signing (Reg. No	Attorney/Agent CAROL L. FRANCIS  DO BOZICEVIC, FIELD		. A	
	Signatur	1/2 /15/	naw		·
	Date	March 4, 2004	<u> </u>	<u> </u>	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and

Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**EXPRESS MAIL LABEL NO. EV 333 997 905US** 

## Express Mail No. EV 333 997 905US

## INFORMATION DISCLOSURE STATEMENT

Address to:
Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Attorney Docket	IRVN-009CON
First Named Inventor	KEIRSTEAD, HANS S.
Application Number	10/661,105
Confirmation No.	6563
Filing Date	September 12, 2003
Group Art Unit	1651
Examiner Name	

Title: "OLIGODENDROCYTES DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR REMYELINATION AND TREATMENT OF SPINAL CORD INJURY"

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. IRVN-009CON may be charged thereon.

By:

Respectfully submitted,

Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP

Date: March 4, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

eny Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTC 10/661,105 Application Number INFORMATION DISCLOSURE September 12, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor KEIRSTEAD, HANS S. Art Unit 1651 (use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number IRVN-009CON

			U.S. PATENT I	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2002/019046	02-14-2002	M.K. Carpenter	190.001.000

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> –Number <sup>4</sup> –Kind Code <sup>5</sup> ( <i>if known</i> )		Applicant of Cited Document		
		WO 01/088104	11-22-2001	Geron Corporation	, ,	
		WO 01/028342	04-26-2001	Washington University		$oxed{oxed}$

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>				
		Blakemore W. F. et al., "The Origin of Remyelinating Cells in the Central Nervous System." Journal of Neuroimmunology, July 1, 1999, Vol. 98, No. 1, pages 69-76			
		Nistor, G.I. et al., "Induction High Purity Oligodendrocyte Cultures from Human Embryonic Stem Cells." Biosciences Information Services, Philadelphia, PA US; 2002, Vol. 2002, pages Abstract No.: 726.16			
		Zhang, S. C. et al., "In Vitro Differentiation of Transplantable Neural Precursors form Human Embryonic Stem Cells." Nature Biotechnology December 2001, pages 1129-1133			

Signature	Considered
*EXAMINER: In	tial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered
Include copy of	this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here is
English languag	e Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the publi

Date

which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Examiner